<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Imipramine</id>
	<title>Imipramine - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Imipramine"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Imipramine&amp;action=history"/>
	<updated>2026-04-27T01:25:14Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Imipramine&amp;diff=4968074&amp;oldid=prev</id>
		<title>Prab at 22:26, 13 September 2023</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Imipramine&amp;diff=4968074&amp;oldid=prev"/>
		<updated>2023-09-13T22:26:18Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[File:Imipramine.svg|Imipramine|thumb]]&lt;br /&gt;
[[File:Imipramine-3D-balls.png|Imipramine-3D-balls|thumb]]&lt;br /&gt;
Imipramine is a tricyclic antidepressant that continues to be widely used in the therapy of [[depression]]. &lt;br /&gt;
{{livtox}}&lt;br /&gt;
Imipramine can cause mild and transient serum enzyme elevations and is rare cause of clinically apparent acute cholestatic liver injury.&lt;br /&gt;
{{moa}}&lt;br /&gt;
Imipramine (im ip&amp;#039; ra meen) is a dibenzazepine derived tricyclic antidepressant which acts by inhibition of serotonin and norepinephrine reuptake within synaptic clefts in the central nervous system, thus increasing brain levels of these neurotransmitters. &lt;br /&gt;
{{fda}}&lt;br /&gt;
Imipramine is indicated for therapy of [[depression]] and was approved for this indication in the United States in 1959; it is still widely used, with more than 1 million prescriptions being filled yearly. Imipramine is also used for childhood enuresis. &lt;br /&gt;
{{dose}}&lt;br /&gt;
Imipramine is available in generic forms and under the brand names of Tofranil in 10, 25, and 50 mg tablets and as capsules of 75, 100, 125 and 150 mg for nighttime dosing. The typical recommended dose for [[depression]] in adults is 75 to 100 mg daily in divided doses, increasing gradually to a maximum of 200 mg daily. Imipramine can also be given as a single nighttime dose. The recommended dose in children (ages 6 years or above) is 25 to 75 mg daily 1 hour before bedtime.&lt;br /&gt;
{{se}}&lt;br /&gt;
Common side effects include [[dizziness]], [[headache]], [[drowsiness]], restlessness, confusion, gastrointestinal upset, [[increased appetite]], [[weight gain]], blurred vision, [[dry mouth]] and urinary retention.&lt;br /&gt;
{{coststubd}}&lt;br /&gt;
{{Antidepressants}}&lt;br /&gt;
{{Navboxes&lt;br /&gt;
| title = [[Pharmacodynamics]]&lt;br /&gt;
| titlestyle = background:#ccccff&lt;br /&gt;
| list1 = &lt;br /&gt;
{{Adrenergic receptor modulators}}&lt;br /&gt;
{{Dopamine receptor modulators}}&lt;br /&gt;
{{Histamine receptor modulators}}&lt;br /&gt;
{{Ion channel modulators}}&lt;br /&gt;
{{Monoamine reuptake inhibitors}}&lt;br /&gt;
{{Muscarinic acetylcholine receptor modulators}}&lt;br /&gt;
{{Serotonin receptor modulators}}&lt;br /&gt;
{{Sigma receptor modulators}}&lt;br /&gt;
}}&lt;br /&gt;
{{Tricyclics}}&lt;br /&gt;
{{Portal bar | Medicine}}&lt;br /&gt;
[[Category:Alpha-1 blockers]]&lt;br /&gt;
[[Category:CYP2D6 inhibitors]]&lt;br /&gt;
[[Category:D2 antagonists]]&lt;br /&gt;
[[Category:Dibenzazepines]]&lt;br /&gt;
[[Category:Dimethylamino compounds]]&lt;br /&gt;
[[Category:Glycine receptor antagonists]]&lt;br /&gt;
[[Category:H1 receptor antagonists]]&lt;br /&gt;
[[Category:Muscarinic antagonists]]&lt;br /&gt;
[[Category:Nicotinic antagonists]]&lt;br /&gt;
[[Category:Novartis brands]]&lt;br /&gt;
[[Category:Serotonin receptor antagonists]]&lt;br /&gt;
[[Category:Serotonin–norepinephrine reuptake inhibitors]]&lt;br /&gt;
[[Category:Tricyclic antidepressants]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>